There are more than 300 kinds of cancer and each patient’s cancer is unique. Importantly, it can take months to determine which patients will respond to their treatment and who will need another option. This is time that many patients and their families simply cannot afford. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline
Notable
Biotechnology Research
Foster City, California 3,568 followers
Notable is a mission-driven company transforming the way cancer is treated
About us
Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable’s proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product’s medical impact and commercial value faster, higher, and more likely than traditional drug development.
- Website
-
http://notablelabs.com
External link for Notable
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Foster City, California
- Type
- Privately Held
- Founded
- 2014
Locations
-
Primary
320 Hatch Dr
Foster City, California, US
Employees at Notable
Updates
-
Notable is building an innovative environment at the intersection of technology and biology. Our engineers, cell biologists, data scientists, drug developers and diagnostics experts work side-by-side in interdisciplinary teams with the goal of transforming the traditional concept of standard-of-care by pioneering a novel responder-focused approach to drug development. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline
-
Notable is harnessing our predictive medicine platform to build a pipeline of novel therapeutics. By matching the right drug with the right patient, we aim to increase the clinical response rate of the therapeutics in our pipeline while reducing the risk, time and cost of development. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation, #pipeline
-
Our predictive medicine platform employs advanced technology, including flow cytometry and robotic automation, to bio-simulate treatment of each patient’s cancer at the cellular level. Our biological response database provides improved insight into patient response, helping us to identify promising drugs to develop into new therapeutics. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #flowcytometry, #roboticautomation
-
Notable reposted this
Getting the right treatment to the right patient, the first time, is critical for people fighting cancer. By combining existing de-risked drugs with a proprietary predicted responder diagnostic, we're working to ensure that a patient will only receive treatment that is likely to work for them. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #drugdevelopment, #hematology, #hematologists, #bloodcancer, #leukemia, #MDS, #cancerresearch
-
Getting the right treatment to the right patient, the first time, is critical for people fighting cancer. By combining existing de-risked drugs with a proprietary predicted responder diagnostic, we're working to ensure that a patient will only receive treatment that is likely to work for them. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #drugdevelopment, #hematology, #hematologists, #bloodcancer, #leukemia, #MDS, #cancerresearch
-
Our mission at Notable is to develop therapeutics that work predictably for people fighting cancer. We are dedicated to developing novel therapeutics so that physicians will know whether a patient is likely to benefit before they recommend a treatment. #biopharma, #biopharmaceuticals, #therapeutics, #cancer, #AML, #drugdevelopment, #hematology, #hematologists, #bloodcancer, #leukemia, #MDS, #cancerresearch
-
It can take months to determine who will respond to a specific cancer treatment. This is time that many patients and their families simply cannot afford. Acute myeloid leukemia is a deadly disease and as few as 15% of patients fighting relapsed/refractory AML respond to the current standard of care. Notable #CSO Joseph Wagner shares his thoughts about unmet medical needs for patients fighting cancer. #AcuteMyeloidLeukemia #AML #cancer
-
ICYMI, Notable Labs poster, “Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples,” presented at the American Association for Cancer Research (AACR) 2024 in San Diego, CA (Abstract 2548). Kudos to Lokesh Patil, Notable Labs Platform Lead, who served as the lead author and poster presenter, as well as Oregon Health & Science University abstract co-authors Nicola Long and Cristina Tognon, PhD. These data suggest Ex vivo drug sensitivity assay using cryopreserved patient samples in the PPMP assay can predict clinical response. Please visit https://lnkd.in/ek4ztm7D. #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS
-
Check out Notable Labs poster, “Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients,” presented last week at the American Association for Cancer Research (AACR) 2024 in San Diego, CA (Abstract 5178). Congratulations to Markus Lacher, Notable Labs VP of R&D who served as the lead author and poster presenter. These data suggest a strong correlation between volasertib resistant fractions treated with 31.6 and 100 nM of volasertib and AUCs, which could represent a suitable metric to stratify patients into responders and non-responders. These preliminary metrics predict that 32-33% of de novo patients and 25% of R/R AML patients would be predicted to be responders if they were treated with volasertib. Please visit https://lnkd.in/ex6Wk3kV Stanford Department of Medicine #precisionmedicine #precisononcology #hematology #hematologists #bloodcancer #AML #MDS #Volasertib